CN113645975A - 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 - Google Patents

用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 Download PDF

Info

Publication number
CN113645975A
CN113645975A CN202080026737.4A CN202080026737A CN113645975A CN 113645975 A CN113645975 A CN 113645975A CN 202080026737 A CN202080026737 A CN 202080026737A CN 113645975 A CN113645975 A CN 113645975A
Authority
CN
China
Prior art keywords
erdatinib
patient
fgfr
treatment
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026737.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·Z·德波雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN113645975A publication Critical patent/CN113645975A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
CN202080026737.4A 2019-03-29 2020-03-27 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂 Pending CN113645975A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
EP19166429.1 2019-03-29
US201962833395P 2019-04-12 2019-04-12
US62/833395 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
CN113645975A true CN113645975A (zh) 2021-11-12

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026737.4A Pending CN113645975A (zh) 2019-03-29 2020-03-27 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂

Country Status (15)

Country Link
US (1) US20220175768A1 (cg-RX-API-DMAC7.html)
EP (2) EP3946340A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022527482A (cg-RX-API-DMAC7.html)
KR (1) KR20210143878A (cg-RX-API-DMAC7.html)
CN (1) CN113645975A (cg-RX-API-DMAC7.html)
AU (1) AU2020253054B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130773A1 (cg-RX-API-DMAC7.html)
IL (1) IL286727A (cg-RX-API-DMAC7.html)
JO (1) JOP20210260A1 (cg-RX-API-DMAC7.html)
MA (1) MA55486A (cg-RX-API-DMAC7.html)
MX (1) MX2021011943A (cg-RX-API-DMAC7.html)
PH (1) PH12021552352A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109854RA (cg-RX-API-DMAC7.html)
WO (1) WO2020201138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
IL312063A (en) 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
WO2023159216A1 (en) 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
IL322667A (en) 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
CN120731077A (zh) 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
TW201839399A (zh) * 2017-02-06 2018-11-01 比利時商健生藥品公司 癌症治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TABERNERO, JOSEP: "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 33, no. 30, 31 August 2015 (2015-08-31), pages 3405 *
杨友法等: "《精编临床泌尿外科学》", vol. 2018, 30 June 2018, 上海交通大学出版社, pages: 203 - 204 *

Also Published As

Publication number Publication date
EP4548935A3 (en) 2025-08-06
JP2026048748A (ja) 2026-03-17
MX2021011943A (es) 2021-11-03
MA55486A (fr) 2022-02-09
PH12021552352A1 (en) 2022-09-05
SG11202109854RA (en) 2021-10-28
EP3946340A1 (en) 2022-02-09
AU2020253054A1 (en) 2021-09-30
JP2022527482A (ja) 2022-06-02
CA3130773A1 (en) 2020-10-08
WO2020201138A1 (en) 2020-10-08
BR112021019203A2 (pt) 2021-11-30
KR20210143878A (ko) 2021-11-29
EP4548935A2 (en) 2025-05-07
AU2020253054B2 (en) 2026-01-08
JOP20210260A1 (ar) 2023-01-30
IL286727A (en) 2021-10-31
US20220175768A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
TW201839399A (zh) 癌症治療
JP2025156297A (ja) 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤
TWI863962B (zh) 癌症治療
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2026505598A (ja) 高リスク筋層非浸潤性膀胱癌の治療のためのfgfrチロシンキナーゼ阻害剤
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064232

Country of ref document: HK